nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.09.2009 | Original Paper

Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion

verfasst von: Fang Fang, Ping Chen, Xin Wu, Li Yang, Xun Yang, Zhen-Xiang Xi, Bin-Wen Zhou, Xi-Kun Zhou, Zhi-Yong Qian, Bo Xiao, Yu-Quan Wei

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Malignant pleural effusion (MPE) is a common clinical problem in patients with advanced cancer. Evidence suggests that tumor-mediated angiogenesis and enhanced vascular permeability in the pleural wall are due to high levels of vascular endothelial growth factor (VEGF), which plays an important role in the pathogenesis of MPE. The present study was designed to test whether the recombinant adenovirus-mediated delivery of human endostatin (Ad-hEndo), one of the potent inhibitors of angiogenesis, would inhibit the formation and progression of MPE.

Methods

We developed a novel mouse model of MPE by injecting Lewis lung carcinoma (LLC) cells directly into pleural cavity of C57BL/6 mice. To evaluate the therapeutic effects of endostatin in this MPE model, we injected the Ad-hEndo into the pleural cavity of MPE-bearing mice three times with the 3-day interval.

Results

We found that this treatment resulted in significant reduction in pleural effusion volume, the number of pleural tumor foci, microvessel density, and vascular permeability, while it significantly prolonged the survival time. In addition, VEGF level of MPE in the group administered with the Ad-hEndo was obviously decreased as compared with that in the two control groups administered with null-adenovirus (Ad-null) or normal saline.

Conclusions

Our work provides a rationale for future studies toward evaluating the effectiveness of the adenovirus-based endostatin therapy for MPE.

Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J et al (2000) Management of malignant pleural effusions. Am J Respir Crit Care Med 162:1987–2001

Burrows CM, Mathews WC, Colt HG (2000) Predicting survival in patients with recurrent symptomatic malignant pleural effusions. Chest 117:73–78. doi:10.1378/chest.117.1.73 PubMedCrossRef

Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435–439. doi:10.1038/380435a0 PubMedCrossRef

Ceyhan BB, Ozgun S, Celikel T, Yalcin M, Koc M (1996) IL-8 in pleural effusion. Respir Med 90:215–221. doi:10.1016/S0954-6111(96)90290-5 PubMedCrossRef

Cheng D, Lee YCG, Rogers JT, Perkett EA, Moyers JP, Rodriguez RM et al (2000) Vascular endothelial growth factor level correlates with transforming growth factor-β isoform levels in pleural effusions. Chest 118:1747–1753. doi:10.1378/chest.118.6.1747 PubMedCrossRef

Dkhissi F, Lu H, Soria C, Opolon P, Griscelli F, Liu H et al (2003) Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 14:997–1008. doi:10.1089/104303403766682250 PubMedCrossRef

Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS et al (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439–442. doi:10.1038/380439a0 PubMedCrossRef

Folkman J (1995) Seminars in Medicine of the Beth Israel Hospital, Boston Clinical applications of research on angiogenesis. N Engl J Med 333:1757–1763. doi:10.1056/NEJM199512283332608 PubMedCrossRef

Gahéry-Ségard H, Juillard V, Gaston J, Lengagne R, Pavirani A, Boulanger P et al (1997) Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Eur J Immunol 27:653–659. doi:10.1002/eji.1830270312 PubMedCrossRef

Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF et al (2002) The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 16:1802–1804PubMed

Hamed EA, El-Noweihi AM, Mohamed AS, Mahmoud A (2004) Vasoactive mediators (VEGF and TNF-a) in patients with malignant and tuberculous pleural effusions. Respirology 9:81–86. doi:10.1111/j.1440-1843.2003.00529.x PubMedCrossRef

Hampl M, Tanaka T, Albert PS, Lee J, Ferrari N, Fine HA (2001) Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Hum Gene Ther 12:1713–1729. doi:10.1089/104303401750476221 PubMedCrossRef

Herbst RS, Fidler IJ (2000) Angiogenesis and lung cancer: potential for therapy. Clin Cancer Res 6:4604–4606PubMed

Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C et al (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792–3803. doi:10.1200/JCO.2002.11.061 PubMedCrossRef

Huang BJ, Liu RY, Huang JL, Liang ZH, Gao GF, Wu JX et al (2007) Long-Term toxicity studies in Canine of E10A, an adenoviral vector for human endostatin gene. Hum Gene Ther 18:207–221. doi:10.1089/hum.2006.149 PubMedCrossRef

Leopold PL, Wendland RL, Vincent T, Crystal RG (2006) Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J Virol 80:10237–10247. doi:10.1128/JVI.00512-06 PubMedCrossRef

Li G, Tian L, Hou JM, Ding ZY, He QM, Feng P et al (2005) Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 11:4217–4224. doi:10.1158/1078-0432.CCR-04-2117 PubMedCrossRef

Li L, Liu RY, Huang JL, Liu QC, Li Y, Wu PH et al (2006) Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer 118:2064–2071. doi:10.1002/ijc.21585 PubMedCrossRef

Light RW (2002) Talc for pleurodesis? Chest 122:1506–1508. doi:10.1378/chest.122.5.1506 PubMedCrossRef

Marx J (2003) Angiogenesis A boost for tumor starvation. Science 301:452–454. doi:10.1126/science.301.5632.452 PubMedCrossRef

Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ (2004) Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 170:377–382. doi:10.1164/rccm.200311-1579OC PubMedCrossRef

Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ et al (2006) ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 16:15–26PubMed

Momi H, Matsuyama W, Inoue K, Kawabata M, Arimura K, Fukunaga H et al (2002) Vascular endothelial growth factor and proinflammatory cytokines in pleural effusions. Respir Med 96:817–822. doi:10.1053/rmed.2002.1364 PubMedCrossRef

O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285. doi:10.1016/S0092-8674(00)81848-6 PubMedCrossRef

Sack U, Hoffman M, Zhao XJ, Chan KS, Hui DS, Gosse H et al (2005) Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 25:600–604. doi:10.1183/09031936.05.00037004 PubMedCrossRef

Setoguchi Y, Jaffe HA, Chu CS, Crystal RG (1994) Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 10:369–377PubMed

Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S et al (2006) Nuclear factor-kappaB affects tumour progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34:142–150. doi:10.1165/rcmb.2005-0130OC PubMedCrossRef

Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN et al (2007) Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 67:9825–9834. doi:10.1158/0008-5472.CAN-07-1064 PubMedCrossRef

Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S et al (2008) Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 178(1):50–59PubMedCrossRef

Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P et al (2005) Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 11:7444–7453. doi:10.1158/1078-0432.CCR-05-0405 PubMedCrossRef

Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A et al (2007) A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 13:4456–4466. doi:10.1158/1078-0432.CCR-07-0403 PubMedCrossRef

Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A (2001) Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 18:1093–1098PubMed

Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A et al (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223–231. doi:10.1200/JCO.2003.12.120 PubMedCrossRef

Tomimoto H, Yano S, Muguruma H, Kakiuchi S, Sone S (2007) Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions. J Med Invest 54:146–153. doi:10.2152/jmi.54.146 PubMedCrossRef

Van Ginkel FW, Liu C, Simecka JW, Dong JY, Greenway T, Frizzell RA et al (1995) Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther 6:895–903. doi:10.1089/hum.1995.6.7-895 PubMedCrossRef

Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG (2007) Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol 81:13801–13808. doi:10.1128/JVI.01246-07 PubMedCrossRef

Wu Y, Yang L, Hu B, Liu JY, Su JM, Luo Y et al (2005) Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs 16:551–557. doi:10.1097/00001813-200506000-00011 PubMedCrossRef

Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S (1999) Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 48:396–400. doi:10.1007/s002620050592 PubMedCrossRef

Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM et al (2000a) Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 157:1893–1903PubMed

Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ et al (2000b) Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6:957–965PubMed

Yei S, Mittereder N, Wert S, Whitsett JA, Wilmott RW, Trapnell BC (1994) In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 5:731–744. doi:10.1089/hum.1994.5.6-731 PubMedCrossRef

Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB Jr et al (1999) Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5:3364–3368PubMed

Titel: Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion
verfasst von: Fang Fang
Ping Chen
Xin Wu
Li Yang
Xun Yang
Zhen-Xiang Xi
Bin-Wen Zhou
Xi-Kun Zhou
Zhi-Yong Qian
Bo Xiao
Yu-Quan Wei
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0555-y

Springer Medizin

Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion